Late-Stage Lead Diversification Coupled with Quantitative Nuclear Magnetic Resonance Spectroscopy to Identify New Structure-Activity Relationship Vectors at Nanomole-Scale Synthesis: Application to Loratadine, a Human Histamine H


Journal

Journal of medicinal chemistry
ISSN: 1520-4804
Titre abrégé: J Med Chem
Pays: United States
ID NLM: 9716531

Informations de publication

Date de publication:
09 07 2020
Historique:
pubmed: 29 5 2020
medline: 28 11 2020
entrez: 29 5 2020
Statut: ppublish

Résumé

An experimental approach is described for late-stage lead diversification of frontrunner drug candidates using nanomole-scale amounts of lead compounds for structure-activity relationship development. The process utilizes C-H bond activation methods to explore chemical space by transforming candidates into newly functionalized leads. A key to success is the utilization of microcryoprobe nuclear magnetic resonance (NMR) spectroscopy, which permits the use of low amounts of lead compounds (1-5 μmol). The approach delivers multiple analogues from a single lead at nanomole-scale amounts as DMSO-

Identifiants

pubmed: 32462865
doi: 10.1021/acs.jmedchem.0c00483
doi:

Substances chimiques

Histamine H1 Antagonists, Non-Sedating 0
Metalloporphyrins 0
Recombinant Proteins 0
Loratadine 7AJO3BO7QN
Cytochrome P-450 Enzyme System 9035-51-2
Dimethyl Sulfoxide YOW8V9698H

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

7268-7292

Auteurs

Manjinder S Lall (MS)

Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States.

Asser Bassyouni (A)

Pfizer Worldwide Research and Development, Science Center Drive, San Diego, California 92121, United States.

James Bradow (J)

Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States.

Maria Brown (M)

Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States.

Mark Bundesmann (M)

Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States.

Jinshan Chen (J)

Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States.

Gregory Ciszewski (G)

Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States.

Anne E Hagen (AE)

Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States.

Dennis Hyek (D)

Spectrix Analytical Services, LLC, 410 Sackett Point Road, Bldg 20, North Haven, Connecticut 06473, United States.

Stephen Jenkinson (S)

Pfizer Worldwide Research and Development, Science Center Drive, San Diego, California 92121, United States.

Bo Liu (B)

Spectrix Analytical Services, LLC, 410 Sackett Point Road, Bldg 20, North Haven, Connecticut 06473, United States.

R Scott Obach (RS)

Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States.

Senliang Pan (S)

Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States.

Usa Reilly (U)

Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States.

Neal Sach (N)

Pfizer Worldwide Research and Development, Science Center Drive, San Diego, California 92121, United States.

Daniel J Smaltz (DJ)

Pfizer Worldwide Research and Development, 1 Portland Street, Cambridge, Massachusetts 02139, United States.

Douglas K Spracklin (DK)

Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States.

Jeremy Starr (J)

Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States.

Melissa Wagenaar (M)

Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States.

Gregory S Walker (GS)

Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH